Description

Neurocrine Biosciences’ Soleno Acquisition: Is VYKAT XR The Next Big Franchise?

Neurocrine Biosciences reported strong financial and operational results for the second quarter of 2026, highlighting progress across its diversified commercial portfolio and pipeline development. Total revenue exceeded $950 million, representing nearly 40% year-over-year growth, with net product sales from INGREZZA, CRENESSITY, and VYKAT XR contributing significantly. INGREZZA delivered $716 million in net sales, up 15% year-over-year, supported by record new patient starts and sustained demand. CRENESSITY generated $184 million, reflecting steady launch execution and expanding prescriber adoption, reaching about 15% penetration of the diagnosed patient population. VYKAT XR, following the acquisition of Soleno Therapeutics, contributed $54 million for the quarter (with pro forma sales at $94 million), aligning with expectations as integration progresses. The acquisition of Soleno for approximately $2.9 billion was financed with cash on hand, leaving Neurocrine Biosciences with roughly $500 million in cash and no debt.